相关实验视频

Updated: Jun 25, 2025

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

达帕格利弗洛辛通过PI3K-Akt-eNOS通路改善后肢缺血的血管生成

Li Han¹, Guoxin Ye¹, Wenjing Su¹

¹Department of Geriatrics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Kongjiang Road 1665, Shanghai 200092, China.

|May 24, 2024

概括

达帕格利弗洛辛通过激活PI3K-Akt-eNOS通路,促进外围动脉疾病中的血管生成. 这提高了血液流动和毛细血管密度,为缺血性疾病提供了一种新的治疗方法.

科学领域:

血管生物学血管生物学
药理学药理学是指药理学的学科.
再生医学是一种再生医学.

背景情况:

糖携运输体2 (SGLT2) 抑制剂对血管有好处,但它们对外周动脉疾病 (PAD) 血管生成的影响尚不清楚.
周围动脉疾病会损害血液流动,导致关键四肢缺血症和心血管风险增加.

研究的目的:

为了研究达帕格利弗洛辛在后肢缺血后对血管生成的影响.
阐明达帕格利弗洛辛对后缺血性血管生成的作用的潜在分子机制.

主要方法:

建立了后肢缺血的老鼠模型,治疗组接受了达帕格利弗洛辛或对照溶液.
使用激光多普勒成像和免疫组织化学评估了血液输液和毛细血管密度.
蛋白质组分析确定了关键信号通路,这些通路在人类静脉内皮细胞 (HUVEC) 中得到进一步验证.

主要成果:

与对照组相比,达帕格利弗洛辛治疗显著改善了后肢血 perfusion 和增加了毛细血管密度.
蛋白质组分析显示PI3K-Akt-eNOS信号通路对于达帕格利弗洛辛的益血管效应至关重要.
实验室研究证实,达帕格利弗洛辛增强HUVEC功能,并提高关键血管新生因子 (p-Akt,p-eNOS,VEGFA) 的调节.

结论:

达帕格利弗洛辛在后肢缺血后促进血管生成,可能通过激活PI3K-Akt-eNOS信号通路.
这些发现表明,达帕格利弗洛辛是对外围动脉疾病的潜在治疗剂.
这项研究为使用达帕格利弗洛辛治疗缺血性血管疾病提供了理论基础.

关键词:

这就是PI3K-Akt-eNOS.血管新生的产生.达帕格利弗洛辛 (Dapagliflozin) 是一种

更多相关视频

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...